AnaptysBio rises on plans to split company

30 September 2025

San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) saw its shares climb by 10.4% to $25.70 in pre-market trading, following its announcement to split into two separate publicly traded companies, each poised for strong, sustainable growth.

Referred to as “Royalty Management Co” and as “Biopharma Co” in the firm’s press release, the two companies’ different business models enable investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company.

AnaptysBio posted revenues of $22.26 million for the second quarter of 2025, and came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK